曲美他嗪辅助标准抗心衰药物治疗慢性心力衰竭的疗效分析

Analysis of the Efficacy of Trimetazidine in the Treatment of Chronic Heart Failure with Standard Anti-heart Failure Drugs

目的分析曲美他嗪辅助标准抗心衰药物治疗慢性心力衰竭临床疗效。方法于2018年8月—2019年8月选择96例慢性心力衰竭患者,将其分成对照组与观察组后,分别给予标准抗心衰药物治疗、曲美他嗪辅助标准抗心衰药物治疗,对比两组治疗效果差异。结果与对照组相比,观察组治疗后hs-CRP[(9.26±0.91)mg/L<(10.33±0.68)mg/L,t=3.16,P<0.05]、LVEF[(49.18±1.45)%>(45.06±1.21)%,t=3.19,P<0.05)]、LVEDVI[(44.85±2.71)mL/m2<(51.66±2.42)mL/m2,t=3.22,P<0.05]、LVESVI[(30.17±1.08)mL/m2<(34.85±1.09)mL/m2,t=2.87,P<0.05]水平改善更显著(P<0.05)。观察组治疗总有效率显著高于对照组(95.83%>83.33%,χ2=4.02,P<0.05),其不良反应发生率显著低于对照组(6.25%<25.00%,χ2=6.40,P<0.05)。结论临床治疗慢性心力衰竭采用曲美他嗪辅助标准抗心衰药物,可有效改善患者炎症因子与心功能水平,且用药不良反应少,疗效显著。

Objective To analyze the clinical efficacy of trimetazidine in the treatment of chronic heart failure with standard anti-heart failure drugs.Methods A total of 96 patients with chronic heart failure from August 2018 to August 2019 were selected and divided into the control group and the observation group.They were treated with standard anti-heart failure drugs and trimetazidine supplemented with standard anti-heart failure drugs.Results Compared with the control group,hs-CRP(9.26±0.91)mg/L<(10.33±0.68)mg/L,t=3.16,P<0.05],LVEF(49.18±1.45)%>(45.06±1.21)%,t=3.19,P<0.05],LVEDVI(44.85±2.71)mL/m2<(51.66±2.42)mL/m2,t=3.22,P<0.05],LVESVI[(30.17±1.08)mL/m2<(34.85±1.09)mL/m2,t=2.87,P<0.05]The level of improvement was more significant(P<0.05).The total effective rate of the observation group was significantly higher than that of the control group(95.83%>83.33%,χ2=4.02,P<0.05),and the incidence of adverse reactions was significantly lower than that of the control group(6.25%<25.00%,χ2=6.40,P<0.05).Conclusion The use of trimetazidine as a standard anti-heart failure drug in the clinical treatment of chronic heart failure can effectively improve the levels of inflammatory factors and cardiac function in patients,and has fewer adverse reactions and significant effects.